Affiliation:
1. Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad + University of Novi Sad, Faculty of Medicine, Novi Sad
Abstract
Introduction. The treatment outcome of adolescents and young adults with
acute lymphoblastic leukemia is much poorer in contrast to pediatric
patients. By changing the concept of the treatment for patients who are
adolescents and young adults with acute lymphoblastic leukemia, especially
with the use of pediatric regimens, significant improvement in survival has
been made (current 5-year survival rate goes up to 70%). Contributing
factors for different outcomes between children and adolescents and young
adults with acute lymphoblastic leukemia. Beside the differences between
pediatric and adult protocols, there are several factors which can explain
the different outcomes between these groups of patients with acute
lymphoblastic leukemia. One of the main factors is different biology of the
leukemias and, on the other side, lower accrual rates in clinical trials in
adolescents and young adults and their specific psychosocial factors, like
poor compliance with the treatment and missed appointments. Current
treatment and novel approaches in the treatment of adolescents and young
adults with acute lymphoblastic leukemia. Current treatment approach to the
adolescent and young adults with acute lymphoblastic leukemia is based on
the pediatric protocols with the risk-adapted strategy, which depends
primarily on the cytogenetics and postinduction minimal/measurable residual
disease. The main goal of the novel treatment, especially with the use of
targeted therapy and innovative immunotherapies incorporated in the
pediatric protocols, is to achieve a deep and durable leukemia-free
survival. To transplant or not to transplant adolescents and young adults
with acute lymphoblastic leukemia is still a matter of debate, particularly
in the era of pediatric regimens and the new sequence algorithm with the
upfront use of novel drugs. Conclusion. Adolescent and young adult patients
with acute lymphoblastic leukemia should be treated in specialized centers
by an experienced multidisciplinary team with close attention to their
particular needs.
Publisher
National Library of Serbia